公开(公告)号：US20240316040A1

公开(公告)日：2024-09-26

申请号：US18259744

申请日：2021-12-29

Applicant: ABBVIE INC.

Inventor： Yihong QIU ,  Ye HUANG ,  Deliang ZHOU

IPC: A61K31/4985 ,  A61K9/00 ,  A61K9/20 ,  A61K9/28

CPC classification number: A61K31/4985 ,  A61K9/0004 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2086 ,  A61K9/2853 ,  A61K9/2866

Abstract: The disclosure describes extended release solid dosage forms comprising upadacitinib, or a pharmaceutically acceptable salt thereof, wherein the solid dosage form provides pH-independent drug release. In particular, the disclosure describes extended release solid dosage forms comprising upadacitinib, or a pharmaceutically acceptable salt thereof, at least one pH-dependent polymer and at least one release control material.

公开(公告)号：US20210046029A1

公开(公告)日：2021-02-18

申请号：US16822892

申请日：2020-03-18

Applicant: AbbVie Inc.

Inventor： Rajkumar CONJEEVARAM ,  Alexandru DEAC ,  Ye HUANG ,  Sean E. MACKEY ,  Randy A. MENGES ,  Jayne ZIMMERMAN

IPC: A61K31/198 ,  A61K9/00 ,  A61K9/10 ,  A61K47/38 ,  A61K47/32 ,  A61K47/10 ,  A61K45/06

Abstract: The present disclosure relates to (a) an improved pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent (b) methods of producing the pharmaceutical composition and (c) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.

公开(公告)号：US20190142777A1

公开(公告)日：2019-05-16

申请号：US16161940

申请日：2018-10-16

Applicant: AbbVie Inc.

Inventor： Rajkumar Conjeevaram ,  Alexandru DEAC ,  Ye HUANG ,  Sean E. MACKEY ,  Randy A. MENGES ,  Jayne Zimmerman

IPC: A61K31/198 ,  A61K45/06 ,  A61K9/00 ,  A61K47/10 ,  A61K9/10 ,  A61K47/38 ,  A61K47/32

Abstract: The present disclosure relates to (a) an improved pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent (b) methods of producing the pharmaceutical composition and (c) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.

公开(公告)号：US20160106765A1

公开(公告)日：2016-04-21

申请号：US14919418

申请日：2015-10-21

Applicant: AbbVie Inc.

Inventor： Benoit CARDINAL-DAVID ,  Vincent S. CHAN ,  Kassibla E. DEMPAH ,  Brian P. ENRIGHT ,  Rodger F. HENRY ,  Raimundo HO ,  Ye HUANG ,  Alexander D. HUTERS ,  Russell C. KLIX ,  Scott W. KRABBE ,  Philip R. KYM ,  Yanbin LAO ,  Xiaochun LOU ,  Sean E. MACKEY ,  Mark A. MATULENKO ,  Peter T. MAYER ,  Christopher P. MILLER ,  James STAMBULI ,  Eric A. VOIGHT ,  Zhi WANG ,  Geoff G. ZHANG ,  Valentino J. STELLA

IPC: A61K31/661 ,  C07F9/06

CPC classification number: C07F9/094 ,  A61K31/661 ,  A61K31/6615 ,  A61K45/06 ,  C07B2200/13 ,  C07C47/277 ,  C07C281/02 ,  C07C309/24 ,  C07F9/06 ,  A61K2300/00

Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

Abstract translation: 本公开内容涉及（a）卡比多巴前药，（b）药物组合和包含卡比多巴前药和/或左旋多巴前药的组合物，和（c）治疗帕金森病和相关病症的方法，包括施用卡比多巴前药和 左旋多巴前药与帕金森病患者。

公开(公告)号：US20250161302A1

公开(公告)日：2025-05-22

申请号：US19027247

申请日：2025-01-17

Applicant: ABBVIE INC.

Inventor： Yihong QIU ,  Ye HUANG ,  Deliang ZHOU

IPC: A61K31/4985 ,  A61K9/00 ,  A61K9/20 ,  A61K9/28

Abstract: The disclosure describes extended release solid dosage forms comprising upadacitinib, or a pharmaceutically acceptable salt thereof, wherein the solid dosage form provides pH-independent drug release. In particular, the disclosure describes extended release solid dosage forms comprising upadacitinib, or a pharmaceutically acceptable salt thereof, at least one pH-dependent polymer and at least one release control material.

公开(公告)号：US20210059968A1

公开(公告)日：2021-03-04

申请号：US16854079

申请日：2020-04-21

Applicant: AbbVie Inc.

Inventor： Alexandru DEAC ,  Ye HUANG ,  John M. LIPARI ,  Alexander RUGGLES ,  Thin Yu TUN

IPC: A61K31/198 ,  A61K47/32 ,  A61K47/10 ,  A61K47/38 ,  A61K9/10 ,  A61K9/00 ,  A61K31/195

Abstract: The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.

公开(公告)号：US20160362431A1

公开(公告)日：2016-12-15

申请号：US15216009

申请日：2016-07-21

Applicant: AbbVie, Inc.

Inventor： Benoit CARDINAL-DAVID ,  Vincent S. CHAN ,  Kassibla DEMPAH ,  Brian P. ENRIGHT ,  Rodger F. HENRY ,  Raimundo HO ,  Ye HUANG ,  Alexander D. HUTERS ,  Russell C. KLIX ,  Scott W. KRABBE ,  Philip R. KYM ,  Yanbin LAO ,  Xiaochun LOU ,  Sean E. MACKEY ,  Mark A. MATULENKO ,  Peter T. MAYER ,  Christopher P. MILLER ,  James STAMBULI ,  Eric A. VOIGHT ,  Zhi WANG ,  Geoff G. ZHANG ,  Valentino J. STELLA

IPC: C07F9/09 ,  A61K31/661 ,  A61K45/06 ,  C07F9/06 ,  A61K31/6615

Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

Abstract translation: 本公开内容涉及（a）卡比多巴前药，（b）药物组合和包含卡比多巴前药和/或左旋多巴前药的组合物，和（c）治疗帕金森病和相关病症的方法，包括施用卡比多巴前药和 左旋多巴前药与帕金森病患者。

公开(公告)号：US20160206584A1

公开(公告)日：2016-07-21

申请号：US15001392

申请日：2016-01-20

Applicant: AbbVie, Inc.

Inventor： Rajkumar CONJEEVARAM ,  Alexandru DEAC ,  Ye HUANG ,  Sean E. MACKEY ,  Randy A. MENGES ,  Jayne ZIMMERMAN

IPC: A61K31/198 ,  A61K47/10 ,  A61K47/38 ,  A61K47/32 ,  A61K9/00 ,  A61K9/10

CPC classification number: A61K31/198 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/10 ,  A61K45/06 ,  A61K47/10 ,  A61K47/32 ,  A61K47/38 ,  A61K2300/00

Abstract: The present disclosure relates to (a) an improved pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent (b) methods of producing the pharmaceutical composition and (c) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.

Abstract translation: 本公开涉及（a）包含左旋多巴活性剂和卡比多巴活性剂的改进的药物组合物（b）制备药物组合物的方法和（c）治疗帕金森病和相关病症的方法，包括将药物组合物施用于 患有帕金森病。

公开(公告)号：US20230129413A1

公开(公告)日：2023-04-27

申请号：US17817191

申请日：2022-08-03

Applicant: AbbVie Inc.

Inventor： Alexandru DEAC ,  Ye HUANG ,  John M. LIPARI ,  Alexander RUGGLES ,  Thin Yu TUN

IPC: A61K31/198 ,  A61K47/32 ,  A61K47/10 ,  A61K47/38 ,  A61K9/10 ,  A61K9/00 ,  A61K31/195

Abstract: The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.

公开(公告)号：US20180021280A1

公开(公告)日：2018-01-25

申请号：US15655078

申请日：2017-07-20

Applicant: AbbVie Inc.

Inventor： Alexandru DEAC ,  Ye HUANG ,  John M. LIPARI ,  Alexander RUGGLES ,  Thin Yu TUN

IPC: A61K31/198 ,  A61K9/00 ,  A61K47/38 ,  A61K9/10 ,  A61K47/32 ,  A61K47/10

CPC classification number: A61K31/198 ,  A61K9/00 ,  A61K9/0053 ,  A61K9/10 ,  A61K31/195 ,  A61K47/10 ,  A61K47/32 ,  A61K47/38 ,  A61K2300/00

Abstract: The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.